Compare AbbVie Inc (ABBV) vs Microsoft (MSFT) Price & Performance

AbbVie (ABBV) trades at $247.91, up 0.76% on the day, with strong technical momentum as the stock approaches resistance near $249. The company demonstrates solid fundamentals with Q2 2026 EPS beating expectations at $3.65 versus $3.61, driven by robust immunology portfolio growth from Skyrizi and Rinvoq offsetting Humira declines. Revenue reached $61.16B in 2025 with a 71.48% gross margin, though net income margin compressed to 9.8%. Recent positive Phase 2 ovarian cancer data and institutional accumulation signal confidence in the pipeline.

Outlook remains positive with analyst consensus target of $281.33 (13.5% upside) and 71% buy ratings, though elevated P/E of 70.05 reflects growth expectations. Key risks include patent cliffs in the 2030s, competitive pressures, and regulatory uncertainties from drug pricing lawsuits. The dividend aristocrat offers income stability with recent $1.73 payout, but investors should monitor execution of oncology pipeline and debt levels at 50.4% of assets.

Microsoft (MSFT) trades at $506.06, up 1.21% today, near its pivot point of $507. The stock shows strong bullish momentum with consistent earnings beats, including Q2 2026 EPS of $4.74 versus $4.24 expected. Revenue growth accelerated to $281.72B in 2025, with a net income margin of 40.31%. Analysts maintain an 80.49% buy rating, citing AI leadership via Azure and Copilot.

Outlook remains positive with a consensus price target of $553.70, though risks include high capital expenditures and competitive pressures in AI. The stock's valuation multiples like P/E of 28.19 are elevated, requiring sustained execution. Near-term support lies at $500, with resistance at $513.